# PS101-mediated ACT With Chemotherapy in Liver Metastases From Cancer of Gastrointestinal Origin

> **NCT04021277** · PHASE1 · TERMINATED · sponsor: **EXACT Therapeutics AS** · enrollment: 11 (actual)

## Conditions studied

- Solid Tumor
- Colorectal Cancer

## Interventions

- **DRUG:** 20 uL/kg PS101
- **DRUG:** 40 uL/kg PS101
- **DEVICE:** Ultrasound

## Key facts

- **NCT ID:** NCT04021277
- **Lead sponsor:** EXACT Therapeutics AS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-17
- **Primary completion:** 2024-08-27
- **Final completion:** 2024-09-24
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Business reason
- **Last updated:** 2024-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04021277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04021277, "PS101-mediated ACT With Chemotherapy in Liver Metastases From Cancer of Gastrointestinal Origin". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04021277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*